AirSculpt Technologies, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US0094961002
USD
4.94
0.13 (2.7%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

518.82 k

Shareholding (Mar 2026)

FII

3.37%

Held by 26 FIIs

DII

53.64%

Held by 8 DIIs

Promoter

42.99%

Is AirSculpt Technologies, Inc. technically bullish or bearish?

20-Sep-2025

As of August 29, 2025, AirSculpt Technologies, Inc. shows a mildly bullish trend with positive momentum from the MACD and daily moving averages, but mixed signals from the KST and OBV suggest cautious monitoring despite strong year-to-date and annual performance compared to the S&P 500.

As of 29 August 2025, the technical trend for AirSculpt Technologies, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish, indicating some positive momentum. The daily moving averages are bullish, supporting the mildly bullish stance. However, the weekly KST and OBV are mildly bearish, and the Dow Theory shows a mildly bearish signal on the weekly timeframe, which adds caution to the outlook.<BR><BR>In terms of performance, the stock has returned 18.5% year-to-date compared to the S&P 500's 12.22%, and it has outperformed the S&P 500 over the past year with a return of 38.83% versus 17.14%. Overall, the current technical stance is mildly bullish, but the mixed signals suggest a need for careful monitoring.

View full answer

Is AirSculpt Technologies, Inc. overvalued or undervalued?

25-Jun-2025

As of August 9, 2024, AirSculpt Technologies, Inc. is considered risky and overvalued due to a negative P/E ratio, high EV to EBITDA, and poor financial metrics, with a year-to-date return of -6.55% compared to the S&P 500's 2.44%.

As of 9 August 2024, the valuation grade for AirSculpt Technologies, Inc. has moved from attractive to risky, indicating a significant shift in its financial outlook. The company is currently deemed overvalued, particularly given its negative P/E ratio and troubling financial metrics. Key ratios include a Price to Book Value of 3.85, an EV to EBITDA of 69.07, and a ROE of -12.46%. <BR><BR>In comparison to its peers, AirSculpt's financial performance appears weak; for instance, Silk Road Medical, Inc. has a P/E of -19.76 and an EV to EBITDA of -18.12, while IRadimed Corp. is in a fair position with a P/E of 37.26 and an EV to EBITDA of 29.31. The company's recent stock performance has been lackluster, with a year-to-date return of -6.55% compared to a modest 2.44% return for the S&P 500, reinforcing the notion of overvaluation amidst a challenging market environment.

View full answer

How big is AirSculpt Technologies, Inc.?

22-Jun-2025

As of Jun 18, AirSculpt Technologies, Inc. has a market capitalization of 315.19 million and reported net sales of 172.10 million with a net profit of -17.13 million over the latest four quarters. Shareholder's funds are at 79.29 million, and total assets amount to 210.00 million.

As of Jun 18, AirSculpt Technologies, Inc. has a market capitalization of 315.19 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 172.10 million, while the sum of Net Profit for the same period is -17.13 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds at 79.29 million and Total Assets at 210.00 million.

View full answer

What does AirSculpt Technologies, Inc. do?

22-Jun-2025

AirSculpt Technologies, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $39 million and a net loss of $3 million as of March 2025. It has a market cap of $315.19 million and key metrics indicating a loss-making status with a debt-to-equity ratio of 0.98.

Overview:<BR>AirSculpt Technologies, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 39 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -3 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 315.19 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.98 <BR>Return on Equity: -12.46% <BR>Price to Book: 4.08 <BR><BR>Contact Details:<BR>Registrar Address: Not available.

View full answer

Should I buy, sell or hold AirSculpt Technologies, Inc.?

22-Jun-2025
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

Risky -

  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of -1.20%, its profits have fallen by -718%
2

Underperformed the market in the last 1 year

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 179 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.72

stock-summary
Return on Equity

-9.37%

stock-summary
Price to Book

2.18

Revenue and Profits:
Net Sales:
39 Million
(Quarterly Results - Mar 2026)
Net Profit:
-2 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
77.06%
0%
77.06%
6 Months
128.7%
0%
128.7%
1 Year
-1.2%
0%
-1.2%
2 Years
23.19%
0%
23.19%
3 Years
-37.15%
0%
-37.15%
4 Years
-17.39%
0%
-17.39%
5 Years
0%
0%
0.0%

AirSculpt Technologies, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
51.12%
EBIT Growth (5y)
-203.19%
EBIT to Interest (avg)
3.47
Debt to EBITDA (avg)
6.08
Net Debt to Equity (avg)
0.98
Sales to Capital Employed (avg)
1.14
Tax Ratio
17.49%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
70.93%
ROCE (avg)
8.55%
ROE (avg)
3.96%

Valuation key factors

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.18
EV to EBIT
-55.87
EV to EBITDA
27.67
EV to Capital Employed
1.69
EV to Sales
1.51
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-3.02%
ROE (Latest)
-9.37%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
Mildly Bearish
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2026stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 19 Schemes (2.97%)

Foreign Institutions

Held by 26 Foreign Institutions (3.37%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is 0.00% vs -17.23% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is 14.29% vs -146.67% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "39.40",
          "val2": "39.40",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "2.20",
          "val2": "2.50",
          "chgp": "-12.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.20",
          "val2": "1.60",
          "chgp": "-25.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.00",
          "val2": "-0.90",
          "chgp": "-11.11%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.40",
          "val2": "-2.80",
          "chgp": "14.29%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-21.60%",
          "val2": "-18.40%",
          "chgp": "-0.32%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is -15.85% vs -7.91% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -46.25% vs -77.78% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "151.80",
          "val2": "180.40",
          "chgp": "-15.85%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "12.80",
          "val2": "18.20",
          "chgp": "-29.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "6.10",
          "val2": "6.20",
          "chgp": "-1.61%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-11.50",
          "val2": "-7.90",
          "chgp": "-45.57%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-11.70",
          "val2": "-8.00",
          "chgp": "-46.25%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-0.10%",
          "val2": "35.00%",
          "chgp": "-3.51%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'26 - YoYstock-summary

Mar'26
Mar'25
Change(%)
Net Sales
39.40
39.40
Operating Profit (PBDIT) excl Other Income
2.20
2.50
-12.00%
Interest
1.20
1.60
-25.00%
Exceptional Items
-1.00
-0.90
-11.11%
Consolidate Net Profit
-2.40
-2.80
14.29%
Operating Profit Margin (Excl OI)
-21.60%
-18.40%
-0.32%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Mar 2026 is 0.00% vs -17.23% in Mar 2025

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Mar 2026 is 14.29% vs -146.67% in Mar 2025

Annual Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
151.80
180.40
-15.85%
Operating Profit (PBDIT) excl Other Income
12.80
18.20
-29.67%
Interest
6.10
6.20
-1.61%
Exceptional Items
-11.50
-7.90
-45.57%
Consolidate Net Profit
-11.70
-8.00
-46.25%
Operating Profit Margin (Excl OI)
-0.10%
35.00%
-3.51%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2025 is -15.85% vs -7.91% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -46.25% vs -77.78% in Dec 2024

stock-summaryCompany CV
About AirSculpt Technologies, Inc. stock-summary
stock-summary
AirSculpt Technologies, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available